Menu Search
Equities

Mediwelcome Healthcare Management & Technology Inc

2159:HKG.HS

Mediwelcome Healthcare Management & Technology Inc

Actions
  • Price (HKD)0.37
  • Today's Change0.00 / 0.00%
  • Shares traded31.20k
  • 1 Year change-47.14%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 05:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mediwelcome Healthcare Management & Technology Inc is a China-based investment holding company that mainly provides comprehensive medical marketing solutions for cardiovascular and cerebrovascular diseases. The Company mainly provides medical conference services, patient education and self-test services, marketing strategy and consulting services, contract research agency services, and Internet hospital services. The Company mainly conducts business within the domestic market.

  • Revenue in HKD (TTM)350.36m
  • Net income in HKD-86.98m
  • Incorporated2019
  • Employees280.00
  • Location
    Mediwelcome Healthcare Management & Technology Inc10/F-12/F, Parkview Place2 East 4th Ring Road, Chaoyang DistrictBeijing ChinaCHN
  • Websitehttp://www.mediwelcome.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.